Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 20, 2019 08:00 ET | Source: Unity Biotechnology, Inc.

UNITY Biotechnology, Inc. to Participate in the 2019 Cantor Global Healthcare Conference

SAN FRANCISCO, Sept. 20, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or...
August 27, 2019 08:00 ET | Source: Unity Biotechnology, Inc.

UNITY Biotechnology, Inc. to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Aug. 27, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or...
August 07, 2019 16:05 ET | Source: Unity Biotechnology, Inc.

UNITY Biotechnology, Inc. Reports Second Quarter 2019 Financial Results and Program Updates

SAN FRANCISCO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing...
July 30, 2019 16:30 ET | Source: Unity Biotechnology, Inc.

UNITY Biotechnology, Inc. Announces Plan for Phase 2 Clinical Study of UBX0101 in Osteoarthritis of the Knee

SAN FRANCISCO, July 30, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing...
July 30, 2019 08:00 ET | Source: Unity Biotechnology, Inc.

UNITY Biotechnology, Inc. To Announce Second Quarter 2019 Financial Results

SAN FRANCISCO, July 30, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing...
June 18, 2019 07:00 ET | Source: Unity Biotechnology, Inc.

UNITY Biotechnology Reports Promising Topline Data from Phase 1 First-in-human Study of UBX0101 in Patients with Osteoarthritis of the Knee

Clinical results support senescent cell elimination with UBX0101 as a potential treatment for osteoarthritis Topline results demonstrate a dose-dependent and clinically meaningful impact on pain ...
May 29, 2019 16:05 ET | Source: Unity Biotechnology, Inc.

UNITY Biotechnology, Inc. and UCSF Enter Exclusive License Agreement on alpha-Klotho Protein for the Treatment of Age-Related Cognitive Decline

SAN FRANCISCO, May 29, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) (NASDAQ:UBX), a biotechnology company developing therapeutics to extend healthspan by slowing, halting or...
May 23, 2019 16:01 ET | Source: Unity Biotechnology, Inc.

UNITY Biotechnology, Inc. to Present at Upcoming Investor Conferences

SAN FRANCISCO, May 23, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or...
May 08, 2019 16:05 ET | Source: Unity Biotechnology, Inc.

UNITY Biotechnology, Inc. Reports First Quarter 2019 Financial Results

SAN FRANCISCO, May 08, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or...
April 29, 2019 16:05 ET | Source: Unity Biotechnology, Inc.

UNITY Biotechnology, Inc. to Announce First Quarter 2019 Financial Results

SAN FRANCISCO, April 29, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or...